NeuroABC | Changing How Neurodegenerative Diseases are Researched

Beckman logomark

Changing how neurodegenerative diseases are researched, investigated, diagnosed and monitored.
The promising pipeline of blood-based biomarkers in the Neuro ACCESS Biomarker Collection meets a full range of neurodegenerative research needs from early translation research to full scale test commercialization.

Partnering with Beckman Coulter provides ACCESS to a breadth of assays across a wide spectrum of diseases coupled with a focused disease-area initiative using a scalable, global platform.

Pharma & CRO

Effective technology transfer is essential to move novel assays from research into clinical labs. Running clinical trials on the same platform intended for future in vitro diagnostic (IVD) testing gives you ACCESS to a strategic advantage by aligning research with scalable diagnostic implementation.

Learn More

Core Labs

To increase accessibility for Alzheimer's disease and neurodegenerative disease research, there is a need to bring research capabilities in house to reduce turn around time and outsourcing. ACCESS the right partner to position your lab for future success.

Learn More

Let’s Talk ACCESS to NeuroABC

See what ACCESS to the NeuroABC biomarker collection can mean for your organization. Request a no-obligation consult with a Beckman Coulter neurodegenerative solutions specialist.

A Strategic Partner in Pre-Clinical and Clinical Neurodegenerative Disease Research

Working with the Beckman Coulter ACCESS Biomarker Collection establishes a partnership for research sponsors and CROs that can span from early clinical feasibility to widespread commercial availability and scalability. Throughout the collaboration, research organizations have access to a growing portfolio of blood-based biomarkers, assays, and support services aligned to their business objectives. It’s the type of partnership that’s ideal for forward-looking organizations acutely aware of speed-to-commercialization issues and the advantages of deploying globally on high-throughput instruments already in field.

EASILY SCALABLE

RAPIDLY COMMERCIALIZED

GLOBALLY DEPLOYABLE

Bridge the Platform Gap

A Unique Core Lab Insourcing Opportunity

Outsourced research work increases time to test results. A NeuroABC partnership represents a strategic first step in the pursuit of a new standard of care for the early detection and treatment of neurodegenerative diseases.

What exists today as a pipeline of blood-based biomarkers and RUO assays points toward a possible future of groundbreaking diagnostics. Core labs with in-house access to the right neurodegenerative pipeline on a high-throughput, highly precise, and reproducible platform will be positioned to lead the way.

Accelerate Insourcing

A Unique Core Lab Insourcing Opportunity

Beckman Coulter has a roadmap containing biomarkers of tau and amyloid pathology and a proven track record of delivering high quality IVD assays.

Blood-based Neurology Disease Assays

Beckman Coulter has a roadmap containing biomarkers of tau and amyloid pathology and a proven track record of delivering high quality IVD assays.

Blood-based Neurodegenerative Disease Assays (RUO)

p-Tau217	IFU	DOWNLOAD PDF
GFAP	IFU	DOWNLOAD PDF
NfL	IFU	DOWNLOAD PDF
APOE ε4	IFU	DOWNLOAD PDF
β-Amyloid 1-42	IFU	COMING SOON
BD-Tau	IFU	COMING SOON

Research Use Only Assays in Development

MTBR-Tau (CSF-based)

TDP-43

Assay has been granted Breakthrough Device Designation (BDD) from the U.S. FDA

p-Tau217/ß-AmyIoid 1-42 Plasma Ratio*

Biomarker Research Pipeline Areas of Focus

Amyloid pathology landscape

Early Tau pathology detection

Co-pathologies for a range of neurodegnerative diseases

Proteotypic assays for genetic risk stratification

In addition to its robust RUO program, Beckman Coulter is actively developing plans to submit a pTau217/Aß ratio blood-based assay for amyloid pathology to the FDA.

Blood-based Neurology Disease Assays

Beckman Coulter has a roadmap containing biomarkers of tau and amyloid pathology and a proven track record of delivering high quality IVD assays.

Access 2

Access 2*
Immunoassay Analyzer

Learn more

DxI 9000

DxI 9000
Immunoassay Analyzer

Learn more

*p-Tau and ß-Amyloid 1-42 only run on DxI 9000

Choose a Partner Who’s Rapidly Changing the Research and Diagnostics Landscape

PR Newswire^®

“Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease”
Read article
Global Alzheimer's Platform Foundation

“Beckman Coulter Diagnostics Joins the Transformative Bio-Hermes-002 Study as New Partner”
Read article
PR Newswire^®

“Beckman Coulter Receives FDA Breakthrough Device Designation for Alzheimer's Disease Blood Test”
Read article
ALZpath

“ALZpath Signs Licensing Agreement with Beckman Coulter Diagnostics to Provide Proprietary pTau217 Antibody to Develop a Diagnostic Blood Test for Alzheimer’s Disease”
Read article

Let's Talk